Exelixis (EXEL) Operating Expenses (2010 - 2026)
Exelixis' (EXEL) quarterly Operating Expenses came in at $359.5 million in Q2 2026, down 2.47% year-on-year from $368.6 million in Q2 2025, and down 1.09% quarter-over-quarter from $363.4 million in Q1 2026.
Exelixis (EXEL) Operating Expenses (2010 - 2026) Analysis & Trends
Exelixis' Operating Expenses history runs 17 years deep, the most recent figure standing at $359.5 million for Q2 2026.
- On a quarterly basis, Operating Expenses fell 2.47% year-over-year to $359.5 million in Q2 2026; TTM through Apr 2026 was $1.4 billion, a 6.38% decrease from a year earlier, with the FY2026 full-year figure at $1.4 billion, down 7.43% from the prior year.
- Operating Expenses slipped to $359.5 million in Q2 2026 per EXEL's latest filing, from $363.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $489.5 million in Q3 2023 and bottomed at $272.7 million in Q2 2022.
- The 5-year median for Operating Expenses is $368.6 million (2025), against an average of $378.8 million.
- Across the five-year window, Operating Expenses surged 48.73% in 2023 and dropped 17.58% in 2024, its largest moves.
- Year by year, Operating Expenses stood at $472.0 million in 2022, then retreated by 15.71% to $397.9 million in 2023, then gained by 1.41% to $403.5 million in 2024, then slipped by 10.47% to $361.2 million in 2025, then fell by 0.48% to $359.5 million in 2026.
- Per Business Quant, the three latest EXEL Operating Expenses figures stand at $359.5 million (Q2 2026), $363.4 million (Q1 2026), and $361.2 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.10 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.78 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 445.22 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 359.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 359.47 Mn |
| Jan 2, 2026 | 363.45 Mn |
| Oct 3, 2025 | 361.22 Mn |
| Jul 4, 2025 | 354.69 Mn |
| Apr 4, 2025 | 368.59 Mn |
| Jan 3, 2025 | 403.55 Mn |
| Sep 27, 2024 | 403.47 Mn |
| Jun 28, 2024 | 361.30 Mn |
| Mar 29, 2024 | 395.76 Mn |
| Dec 29, 2023 | 397.86 Mn |
| Sep 29, 2023 | 489.50 Mn |
| Jun 30, 2023 | 392.00 Mn |
| Mar 31, 2023 | 379.96 Mn |
| Dec 30, 2022 | 472.00 Mn |
| Sep 30, 2022 | 329.13 Mn |
| Jul 1, 2022 | 335.72 Mn |
| Apr 1, 2022 | 272.74 Mn |
| Dec 31, 2021 | 334.50 Mn |
| Oct 1, 2021 | 276.80 Mn |
| Jul 2, 2021 | 262.17 Mn |